<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Rilonacept" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Rilonacept</book-part-id>
      <title-group>
        <title>Rilonacept</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>4</month>
          <year>2020</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Rifaximin" document-type="chapter">Rifaximin</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Rilpivirine" document-type="chapter">Rilpivirine</related-object>
    </book-part-meta>
    <body>
      <sec id="Rilonacept.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Rilonacept.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Rilonacept is a recombinant interleukin-1 (IL-1) antagonist which is used in the therapy of cryopyrin-associated periodic syndromes (CAPS) and other autoinflammatory conditions. Rilonacept has had limited clinical use and has yet to be linked to cases of clinically apparent, acute liver injury.</p>
        </sec>
        <sec id="Rilonacept.Background">
          <title>Background</title>
          <p>Rilonacept (ril on&#x02019; a sept) is a recombinant fusion protein which includes the extracellular portion of the human IL-1 receptor and the IL-1 receptor accessory protein fused with the Fc portion of human IgG1. Rilonacept binds and inactivates IL-1, acting as an &#x0201c;IL-1 trap&#x0201d;. IL-1 is a key proinflammatory cytokine that is a powerful inducer of fever and inflammation. Excessive production of IL-1 or lack of its inactivation is believed to play a major role in many autoinflammatory conditions and particularly in cold induced autoinflammatory conditions such as cryopyrin associated periodic syndromes (CAPS). IL-1 may also play an important role in inflammatory arthritides and familial Mediterranean fever. In controlled trials and open label studies, rilonacept has been shown to improve symptoms and laboratory abnormalities associated CAPS and, to a lesser extent, in patients with gouty arthritis, juvenile idiopathic arthritis, familial Mediterranean fever and in rare forms of autoinflammatory conditions such as Schnitzler syndrome. Rilonacept was approved for use in the United States in 2010 to treat CAPS. Rilonacept is given by subcutaneous injection in a loading dose of 320 mg and a maintenance dose of 160 mg weekly. Rilonacept is available in vials of 20 mL containing 222 mg of rilonacept under the brand name Arcalyst. The most frequent side effects are injection site reactions, upper respiratory symptoms, headache, nausea and hypertension. Potential serious adverse events include life-threatening infections and hypersensitivity reactions</p>
        </sec>
        <sec id="Rilonacept.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>In clinical trials, ALT elevations were rarely mentioned as an adverse event in patients receiving rilonacept, but minor overall increases in both ALT and AST levels were described (1-4%). The timing, severity and outcome of these elevations were not characterized, but there were no instances of jaundice or clinically apparent liver injury. Most ALT elevations were without symptoms or elevations in bilirubin or alkaline phosphatase and no long term hepatic effects were observed. Patients with autoinflammatory conditions such as CAPS frequently have mild-to-moderate elevations in serum enzymes and typically these improve with treatment using inhibitors of IL-1 signaling. Since its approval, there have been no published reports of hepatotoxicity due to rilonacept, although its use has been limited. In addition, rilonacept has not been linked to cases of reactivation of hepatitis B or exacerbation of chronic hepatitis C which can occur with other cytokines and anticytokines.</p>
          <p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Rilonacept.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>Rilonacept is a recombinant protein and has little hepatic metabolism. Any liver injury due to rilonacept is more likely due to its effect on the immune system or on IL-1 pathways rather than a direct toxic effect on the liver.</p>
        </sec>
        <sec id="Rilonacept.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>Agents that block the proinflammatory pathways of IL-1 and IL-6 share similar activity against autoinflammatory diseases and have little evidence for serious hepatotoxicity. There is no reason to suspect that there may be cross sensitivity to hepatic injury between rilonacept and other immune modulating biologic agents or anti-IL1 blockers such as anakinra, canakinumab and tocilizumab.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="AntirheumaticAgents" document-type="chapter">Antirheumatic Agents</related-object></p>
          <p>Other Drugs in the Subclass, <related-object link-type="booklink" source-id="livertox" document-id="InterleukinRcptAntag" document-type="chapter">Interleukin Receptor Antagonists</related-object>: <related-object link-type="booklink" source-id="livertox" document-id="Anakinra" document-type="chapter">Anakinra</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Canakinumab" document-type="chapter">Canakinumab</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Sarilumab" document-type="chapter">Sarilumab</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Tocilizumab" document-type="chapter">Tocilizumab</related-object></p>
        </sec>
      </sec>
      <sec id="Rilonacept.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
          <bold>REPRESENTATIVE TRADE NAMES</bold>
        </p>
        <p>Rilonacept &#x02013; Arcalyst&#x000ae;</p>
        <p>
          <bold>DRUG CLASS</bold>
        </p>
        <p>Antirheumatic Agents</p>
        <p>
          <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=rilonacept">COMPLETE LABELING</ext-link>
        </p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Rilonacept.CHEMICAL_FORMULA_AND_STRUCTUR">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Rilonacept.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Rilonacept.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Rilonacept.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NO.</th>
                <th id="hd_h_Rilonacept.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Rilonacept.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Rilonacept.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Rilonacept</td>
                <td headers="hd_h_Rilonacept.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">501081-76-1</td>
                <td headers="hd_h_Rilonacept.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C9030-H13932-N2400-O2670-S74</td>
                <td headers="hd_h_Rilonacept.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">No Structure</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Rilonacept.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 20 April 2020</p>
        <p>Abbreviations: IL-1, interleukin 1; CAPS, cryopyrin-associated periodic syndrome.</p>
        <p>Abbreviations: IL1, interleukin 1; CAPS, cryopyrin-associated periodic syndrome; DMARD, disease modifying anti-rheumatic drug; TRAPS, tumor necrosis factor receptor associated periodic syndrome.</p>
        <ref-list id="Rilonacept.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Rilonacept.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Drugs used to treat rheumatic and musculospastic disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 517-53.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity published in 1999 before the availability of rilonacept and other recombinant proteins and anticytokines).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Rilonacept.REF.krensky.2018">
            <mixed-citation publication-type="book">Krensky AM, Azzi JR, Hafler DA. Immunosuppressants and tolerogens. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 637-53.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Rilonacept.REF.goldbachmansky.2008.2432">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Goldbach-Mansky</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Shroff</surname>
                  <given-names>SD</given-names>
                </name>
                <name name-style="western">
                  <surname>Wilson</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Snyder</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Plehn</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Barham</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Pham</surname>
                  <given-names>TH</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.</article-title>
              <source>Arthritis Rheum</source>
              <year>2008</year>
              <volume>58</volume>
              <fpage>2432</fpage>
              <lpage>42</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 5 patients with familial cold autoinflammatory syndrome treated with rilonacept [100-160 mg weekly], all had a clinical response to therapy and 3 had mild, transient elevations in ALT or AST).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18668591</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.hoffman.2008.2443">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hoffman</surname>
                  <given-names>HM</given-names>
                </name>
                <name name-style="western">
                  <surname>Throne</surname>
                  <given-names>ML</given-names>
                </name>
                <name name-style="western">
                  <surname>Amar</surname>
                  <given-names>NJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Sebai</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Kivitz</surname>
                  <given-names>AJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Kavanaugh</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Weinstein</surname>
                  <given-names>SP</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.</article-title>
              <source>Arthritis Rheum</source>
              <year>2008</year>
              <volume>58</volume>
              <fpage>2443</fpage>
              <lpage>52</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 47 adults with CAPS enrolled in a controlled trial of rilonacept vs placebo for 6 weeks followed by a 9 weeks of open therapy and then continuation or withdrawal, "small increases in mean ALT and AST levels" were reported with rilonacept, but these changes were not clinically significant).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18668535</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.church.2009.14">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Church</surname>
                  <given-names>LD</given-names>
                </name>
                <name name-style="western">
                  <surname>McDermott</surname>
                  <given-names>MF</given-names>
                </name>
              </person-group>
              <article-title>Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism.</article-title>
              <source>Nat Clin Pract Rheumatol</source>
              <year>2009</year>
              <volume>5</volume>
              <fpage>14</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Commentary on studies of rilonacept in CAPS [Hoffman and Goldbach-Mansky, 2008]; no mention of hepatotoxicity or ALT elevations during treatment).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">19015646</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.furst.2010.327">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Furst</surname>
                  <given-names>DE</given-names>
                </name>
              </person-group>
              <article-title>The risk of infections with biologic therapies for rheumatoid arthritis.</article-title>
              <source>Semin Arthritis Rheum</source>
              <year>2010</year>
              <volume>39</volume>
              <fpage>327</fpage>
              <lpage>46</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the excess risk of infections during biologic therapy of rheumatoid arthritis mentions that the rate of infections was 2.1% in anakinra treated patients vs 0.4% in controls; infections were primarily pneumonia and skin infections, none were fatal and few were opportunistic infections).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">19117595</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.carroll.2011.533">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Carroll</surname>
                  <given-names>MB</given-names>
                </name>
              </person-group>
              <article-title>The impact of biologic response modifiers on hepatitis B virus infection.</article-title>
              <source>Expert Opin Biol Ther</source>
              <year>2011</year>
              <volume>11</volume>
              <fpage>533</fpage>
              <lpage>44</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of reactivation of hepatitis B by biologic response modifiers; rilonacept has not been linked to reactivation of HBV, although the experience in treating patients with HBsAg has been limited).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21269234</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.dubois.2011.639">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Dubois</surname>
                  <given-names>EA</given-names>
                </name>
                <name name-style="western">
                  <surname>Rissmann</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Cohen</surname>
                  <given-names>AF</given-names>
                </name>
              </person-group>
              <article-title>Rilonacept and canakinumab.</article-title>
              <source>Br J Clin Pharmacol</source>
              <year>2011</year>
              <volume>71</volume>
              <fpage>639</fpage>
              <lpage>41</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Short review of mechanism of action, clinical efficacy and safety of rilonacept and canakinumab; no mention of ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21375570</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.miyamae.2012.109">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Miyamae</surname>
                  <given-names>T.</given-names>
                </name>
              </person-group>
              <article-title>Cryopyrin-associated periodic syndromes: diagnosis and management.</article-title>
              <source>Paediatr Drugs</source>
              <year>2012</year>
              <volume>14</volume>
              <fpage>109</fpage>
              <lpage>17</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the clinical features and pathogenesis [mutation in NLRP3 gene] of cryopyrin associated periodic syndromes [CAPS] and currently available treatments including anakinra [recombinant IL-1Ra], rilonacept [recombinant IL-1 trap] and canakinumab [monoclonal antibody to IL-1 beta]; no mention of ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22335455</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF10">
            <element-citation publication-type="journal">
              <article-title>Drugs for rheumatoid arthritis.</article-title>
              <source>Treat Guidel Med Lett</source>
              <year>2012</year>
              <volume>10</volume>
              <issue>117</issue>
              <fpage>37</fpage>
              <lpage>44</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Concise summary on current therapies of rheumatoid arthritis discusses anakinra and tocilizumab, but not rilonacept or canakinumab).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22538522</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.dinarello.2012.633">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Dinarello</surname>
                  <given-names>CA</given-names>
                </name>
                <name name-style="western">
                  <surname>Simon</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>van der Meer</surname>
                  <given-names>JW</given-names>
                </name>
              </person-group>
              <article-title>Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.</article-title>
              <source>Nat Rev Drug Discov</source>
              <year>2012</year>
              <volume>11</volume>
              <fpage>633</fpage>
              <lpage>52</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the biologic actions of IL-1 and the clinical efficacy and safety of agents that block its activity including anakinra [IL-1Ra], canakinumab [monoclonal antibody to IL-1 beta] and rilonacept [recombinant soluble IL-1 receptor]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22850787</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.hashkes.2012.533">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hashkes</surname>
                  <given-names>PJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Spalding</surname>
                  <given-names>SJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Giannini</surname>
                  <given-names>EH</given-names>
                </name>
                <name name-style="western">
                  <surname>Huang</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Johnson</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Park</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Barron</surname>
                  <given-names>KS</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial.</article-title>
              <source>Ann Intern Med</source>
              <year>2012</year>
              <volume>157</volume>
              <fpage>533</fpage>
              <lpage>41</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 14 patients with familial Mediterranean fever treated with sequential 3 month courses of rilonacept or placebo, attacks were less frequent during rilonacept therapy; no mention of ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23070486</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.hoffman.2012.2091">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hoffman</surname>
                  <given-names>HM</given-names>
                </name>
                <name name-style="western">
                  <surname>Throne</surname>
                  <given-names>ML</given-names>
                </name>
                <name name-style="western">
                  <surname>Amar</surname>
                  <given-names>NJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Cartwright</surname>
                  <given-names>RC</given-names>
                </name>
                <name name-style="western">
                  <surname>Kivitz</surname>
                  <given-names>AJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Soo</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Weinstein</surname>
                  <given-names>SP</given-names>
                </name>
              </person-group>
              <article-title>Long-term efficacy and safety profile of rilonacept in the treatment of cryopyrin-associated periodic syndromes: results of a 72-week open-label extension study.</article-title>
              <source>Clin Ther</source>
              <year>2012</year>
              <volume>34</volume>
              <fpage>2091</fpage>
              <lpage>103</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Analysis of long term efficacy and safety of rilonacept in 101 patients with CAPS treated in an open label study for up to 2 years; mean levels of ALT and AST rose in patients receiving rilonacept [2-4 U/L], and therapy was temporarily discontinued in 2 patients because of ALT elevations).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23031624</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.krause.2012.943">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Krause</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Weller</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Stefaniak</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Wittkowski</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Altrichter</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Siebenhaar</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Zuberbier</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Maurer</surname>
                  <given-names>M</given-names>
                </name>
              </person-group>
              <article-title>Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study.</article-title>
              <source>Allergy</source>
              <year>2012</year>
              <volume>67</volume>
              <fpage>943</fpage>
              <lpage>50</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 8 patients with Schnitzler syndrome treated with rilonacept for up to 1 year, symptoms and inflammatory markers improved and there were "no significant changes in safety laboratory values").</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22583335</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.petryna.2012.2056">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Petryna</surname>
                  <given-names>O</given-names>
                </name>
                <name name-style="western">
                  <surname>Cush</surname>
                  <given-names>JJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Efthimiou</surname>
                  <given-names>P</given-names>
                </name>
              </person-group>
              <article-title>IL-1 Trap rilonacept in refractory adult onset Still's disease.</article-title>
              <source>Ann Rheum Dis</source>
              <year>2012</year>
              <volume>71</volume>
              <fpage>2056</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 3 patients with refractory adult-onset Still disease treated with weekly injections of rilonacept, all had a complete remission maintained for 16-28 months and were able to reduce or stop corticosteroids; no adverse events reported).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22679302</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.lovell.2013.2486">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Lovell</surname>
                  <given-names>DJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Giannini</surname>
                  <given-names>EH</given-names>
                </name>
                <name name-style="western">
                  <surname>Reiff</surname>
                  <given-names>AO</given-names>
                </name>
                <name name-style="western">
                  <surname>Kimura</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Li</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Hashkes</surname>
                  <given-names>PJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Wallace</surname>
                  <given-names>CA</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (sJIA).</article-title>
              <source>Arthritis Rheum</source>
              <year>2013</year>
              <volume>65</volume>
              <fpage>2486</fpage>
              <lpage>96</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 24 children with juvenile idiopathic arthritis treated with rilonacept for up to 2 years, the most common adverse event was injection site reactions; no mention of ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23754188</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.mitha.2013.1285">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Mitha</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Schumacher</surname>
                  <given-names>HR</given-names>
                </name>
                <name name-style="western">
                  <surname>Fouche</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Luo</surname>
                  <given-names>SF</given-names>
                </name>
                <name name-style="western">
                  <surname>Weinstein</surname>
                  <given-names>SP</given-names>
                </name>
                <name name-style="western">
                  <surname>Yancopoulos</surname>
                  <given-names>GD</given-names>
                </name>
                <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>J</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.</article-title>
              <source>Rheumatology (Oxford)</source>
              <year>2013</year>
              <volume>52</volume>
              <fpage>1285</fpage>
              <lpage>92</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 248 patients with acute gouty arthritis treated with 2 doses of rilonacept or placebo once weekly for 16 weeks, acute flares were reduced with rilonacept therapy, but adverse events were similar in the two groups except for injection site reactions; no mention of ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23485476</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.terkeltaub.2013.r25">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Terkeltaub</surname>
                  <given-names>RA</given-names>
                </name>
                <name name-style="western">
                  <surname>Schumacher</surname>
                  <given-names>HR</given-names>
                </name>
                <name name-style="western">
                  <surname>Carter</surname>
                  <given-names>JD</given-names>
                </name>
                <name name-style="western">
                  <surname>Baraf</surname>
                  <given-names>HS</given-names>
                </name>
                <name name-style="western">
                  <surname>Evans</surname>
                  <given-names>RR</given-names>
                </name>
                <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>King-Davis</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Weinstein</surname>
                  <given-names>SP</given-names>
                </name>
              </person-group>
              <article-title>Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.</article-title>
              <source>Arthritis Res Ther</source>
              <year>2013</year>
              <volume>15</volume>
              <fpage>R25</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 225 patients with acute gouty arthritis treated with rilonacept versus indomethacin vs the combination, there were no differences in pain scores with addition of rilonacept; no mention of ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23375025</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.ilowite.2014.2570">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ilowite</surname>
                  <given-names>NT</given-names>
                </name>
                <name name-style="western">
                  <surname>Prather</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Lokhnygina</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Schanberg</surname>
                  <given-names>LE</given-names>
                </name>
                <name name-style="western">
                  <surname>Elder</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Milojevic</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Verbsky</surname>
                  <given-names>JW</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.</article-title>
              <source>Arthritis Rheumatol</source>
              <year>2014</year>
              <volume>66</volume>
              <fpage>2570</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 50 children with juvenile idiopathic arthritis treated with rilonacept or placebo for 4 weeks and then with open label rilonacept for up to 24 weeks, response rates were higher with rilonacept, and 4 patients receiving rilonacept developed elevated ALT levels that were above 5 times ULN in 2 [4%]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24839206</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.sundy.2014.1703">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Sundy</surname>
                  <given-names>JS</given-names>
                </name>
                <name name-style="western">
                  <surname>Schumacher</surname>
                  <given-names>HR</given-names>
                </name>
                <name name-style="western">
                  <surname>Kivitz</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Weinstein</surname>
                  <given-names>SP</given-names>
                </name>
                <name name-style="western">
                  <surname>Wu</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>King-Davis</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Evans</surname>
                  <given-names>RR</given-names>
                </name>
              </person-group>
              <article-title>Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.</article-title>
              <source>J Rheumatol</source>
              <year>2014</year>
              <volume>41</volume>
              <fpage>1703</fpage>
              <lpage>11</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 1315 adults with gout treated with rilonacept or placebo for 16 weeks, rilonacept was associated with fewer gout flares but higher rates of ALT elevations [1.1% vs 0.6%]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25028379</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.chalasani.2015.1340">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Stolz</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Talwalkar</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Reddy</surname>
                  <given-names>KR</given-names>
                </name>
                <etal/>
                <collab>United States Drug Induced Liver Injury Network</collab>
              </person-group>
              <article-title>Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.</article-title>
              <source>Gastroenterology</source>
              <year>2015</year>
              <volume>148</volume>
              <fpage>1340</fpage>
              <lpage>52.e7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, none were attributed to rilonacept or other IL-1 antagonists).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25754159</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.winthrop.2018.s21">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Winthrop</surname>
                  <given-names>KL</given-names>
                </name>
                <name name-style="western">
                  <surname>Mariette</surname>
                  <given-names>X</given-names>
                </name>
                <name name-style="western">
                  <surname>Silva</surname>
                  <given-names>JT</given-names>
                </name>
                <name name-style="western">
                  <surname>Benamu</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Calabrese</surname>
                  <given-names>LH</given-names>
                </name>
                <name name-style="western">
                  <surname>Dumusc</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Smolen</surname>
                  <given-names>JS</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>ESCMID Study Group for Infections in Compromised Hosts (ESGICH). Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).</article-title>
              <source>Clin Microbiol Infect</source>
              <year>2018</year>
              <volume>24</volume>
              <supplement>Suppl 2</supplement>
              <fpage>S21</fpage>
              <lpage>S40</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the risk of infections in patients receiving biologic therapies targeting interleukins and immunoglobulins concludes that patients taking IL-1 targeted agents have a moderate increased risk for infections, should be prescreened for tuberculosis and monitored for infections during therapy).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">29447987</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.garg.2017.94838">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Garg</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>de Jesus</surname>
                  <given-names>AA</given-names>
                </name>
                <name name-style="western">
                  <surname>Chapelle</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Dancey</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Herzog</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Rivas-Chacon</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Muskardin</surname>
                  <given-names>TLW</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist.</article-title>
              <source>JCI Insight</source>
              <year>2017</year>
              <volume>2</volume>
              <comment>pii</comment>
              <elocation-id>94838</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(6 children with IL-1r antagonist deficiency receiving daily injections of anakinra for 3 to 6 years were switched to once-weekly rilonacept and all had complete remissions with improved quality of life; adverse events included upper respiratory infections and gastrointestinal symptoms but no patient discontinued therapy; no mention of ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">28814674</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.mantero.2018.146">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Mantero</surname>
                  <given-names>JC</given-names>
                </name>
                <name name-style="western">
                  <surname>Kishore</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Ziemek</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Stifano</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Zammitti</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Khanna</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Gordon</surname>
                  <given-names>JK</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial.</article-title>
              <source>Clin Exp Rheumatol</source>
              <year>2018</year>
              <volume>36</volume>
              <supplement>Suppl 113</supplement>
              <fpage>146</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 19 patients with systemic sclerosis treated with 6 weekly injections or rilonacept or placebo, symptoms and markers of disease activity did not change with therapy while adverse events included injection site reactions).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">30277862</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.giacomelli.2018.24">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Giacomelli</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Ruscitti</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Shoenfeld</surname>
                  <given-names>Y.</given-names>
                </name>
              </person-group>
              <article-title>A comprehensive review on adult onset Still's disease.</article-title>
              <source>J Autoimmun</source>
              <year>2018</year>
              <volume>93</volume>
              <fpage>24</fpage>
              <lpage>36</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the pathogenesis, clinical features, complications and therapy of adult onset Still&#x02019;s disease mentions that liver test abnormalities have been reported in 37-74% of subjects and that anakinra has been studied in at least 13 small open label trials with response rates of 46-100%, and both canakinumab or rilonacept have been found to be helpful in cases with intolerance or an inadequate response to anakinra).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">30077425</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.crayne.2019.119">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Crayne</surname>
                  <given-names>CB</given-names>
                </name>
                <name name-style="western">
                  <surname>Albeituni</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Nichols</surname>
                  <given-names>KE</given-names>
                </name>
                <name name-style="western">
                  <surname>Cron</surname>
                  <given-names>RQ</given-names>
                </name>
              </person-group>
              <article-title>The Immunology of macrophage activation syndrome.</article-title>
              <source>Front Immunol</source>
              <year>2019</year>
              <volume>10</volume>
              <fpage>119</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the immunopathogenesis of the macrophage activation syndrome, a complication of several systemic inflammatory disorders including juvenile idiopathic arthritis, systemic lupus erythematosus and adult onset Still&#x02019;s disease, characterized by high circulating levels of proinflammatory cytokines which has led to the experimental use of cytokine inhibitors such as anakinra, canakinumab and rilonacept).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">30774631</pub-id>
            </element-citation>
          </ref>
          <ref id="Rilonacept.REF.sfriso.2020.129">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Sfriso</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Bindoli</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Doria</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Feist</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Galozzi</surname>
                  <given-names>P</given-names>
                </name>
              </person-group>
              <article-title>Canakinumab for the treatment of adult-onset Still's disease.</article-title>
              <source>Expert Rev Clin Immunol</source>
              <year>2020</year>
              <volume>16</volume>
              <fpage>129</fpage>
              <lpage>38</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the clinical efficacy and safety of canakinumab for adult-onset Still&#x02019;s disease for which it is not approved in the US, despite evidence for its efficacy in small case series and clinical trials; mentions that small studies of rilonacept in patients with adult-onset Still disease found it to be highly effective in alleviating symptoms and has the advantage of a longer half-life that allows weekly or every other week administration).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">31957508</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Rilonacept.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=Rilonacept+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Rilonacept: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Rilonacept">Trials on Rilonacept: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
